A share price of Akebia Therapeutics Inc. [AKBA] is currently trading at $1.51, up 11.85%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AKBA shares have gain 4.14% over the last week, with a monthly amount glided 0.67%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 2, February 2024, Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 856,950 shares of Akebia’s common stock on January 31, 2024, including an option to purchase 454,950 shares to Nik Grund, Akebia’s newly hired Chief Commercial Officer, and an option to purchase 336,000 shares to Richard Malabre, Akebia’s newly hired Chief Accounting Officer. The options were granted as an inducement material to each such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on August 28, 2023, and kept the price target unchanged to $3.75. On May 31, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $4 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $2 on March 31, 2022. Needham downgraded its rating to a Hold. Mizuho downgraded its rating to Neutral for this stock on March 31, 2022, and downed its price target to $2. In a note dated March 31, 2022, H.C. Wainwright downgraded an Neutral rating on this stock and revised its target price from $10 to $2.
Akebia Therapeutics Inc. experienced fluctuations in its stock price throughout the past year between $0.49 and $1.84. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Akebia Therapeutics Inc. [NASDAQ: AKBA] shares were valued at $1.51 at the most recent close of the market. An investor can expect a potential return of 363.58% based on the average AKBA price forecast.
Analyzing the AKBA fundamentals
Trailing Twelve Months sales for Akebia Therapeutics Inc. [NASDAQ:AKBA] were 193.61M which represents -14.13% decline. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4067 points at the first support level, and at 1.3033 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5767, and for the 2nd resistance point, it is at 1.6433.
Akebia Therapeutics Inc. [AKBA] reported earnings per share of -$0.08 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.08/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.06 per share as compared to estimates of -$0.02 per share, a difference of -$0.04 representing a surprise of -200.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Akebia Therapeutics Inc. [NASDAQ:AKBA] is 1.38. In addition, the Quick Ratio stands at 1.14 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 1.47.
Transactions by insiders
Recent insider trading involved Butler John P., CEO and President, that happened on Feb 01 when 46489.0 shares were sold. SVP, Chief Medical Officer, Burke Steven Keith completed a deal on Feb 01 to sell 24311.0 shares. Meanwhile, SVP, Chief Operating Officer Dahan Michel sold 95478.0 shares on May 25.
